Samantha Semenkow
Stock Analyst at Citigroup
(2.14)
# 2,916
Out of 5,130 analysts
67
Total ratings
40%
Success rate
-1.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Samantha Semenkow
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE | Maintains: Buy | $1,124 → $1,091 | $788.49 | +38.37% | 8 | Jan 8, 2026 | |
| FOLD Amicus Therapeutics | Downgrades: Neutral | $17 → $15 | $14.28 | +1.54% | 2 | Dec 22, 2025 | |
| SYRE Spyre Therapeutics | Initiates: Buy | $64 | $30.61 | +109.08% | 1 | Dec 17, 2025 | |
| WVE Wave Life Sciences | Maintains: Buy | $16 → $30 | $13.84 | +116.76% | 2 | Dec 9, 2025 | |
| GPCR Structure Therapeutics | Maintains: Buy | $60 → $100 | $68.61 | +45.75% | 2 | Dec 9, 2025 | |
| NKTR Nektar Therapeutics | Initiates: Buy | $102 | $39.71 | +156.86% | 1 | Nov 26, 2025 | |
| AGIO Agios Pharmaceuticals | Initiates: Buy | $38 | $28.41 | +33.76% | 1 | Nov 26, 2025 | |
| RYTM Rhythm Pharmaceuticals | Initiates: Buy | $136 | $101.02 | +34.63% | 1 | Nov 25, 2025 | |
| BHVN Biohaven | Maintains: Buy | $28 → $14 | $11.11 | +26.01% | 2 | Nov 13, 2025 | |
| PRME Prime Medicine | Maintains: Neutral | $5 → $4.25 | $3.94 | +7.87% | 5 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $26 | $21.98 | +18.29% | 3 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $33 | $22.72 | +45.25% | 3 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $15 | $14.03 | +6.91% | 5 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Sell | $5 | $18.49 | -72.96% | 3 | Oct 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $10 | $2.10 | +376.19% | 4 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $4 | $1.71 | +133.92% | 3 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.02 | +198.51% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $8 → $15 | $4.56 | +228.95% | 2 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $80 | $11.62 | +588.76% | 2 | Jun 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $14 | $3.33 | +320.42% | 6 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $16 → $15 | $2.07 | +624.64% | 4 | May 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $50 | $26.03 | +92.09% | 3 | Sep 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $56 | $27.55 | +103.27% | 3 | Aug 9, 2023 |
argenx SE
Jan 8, 2026
Maintains: Buy
Price Target: $1,124 → $1,091
Current: $788.49
Upside: +38.37%
Amicus Therapeutics
Dec 22, 2025
Downgrades: Neutral
Price Target: $17 → $15
Current: $14.28
Upside: +1.54%
Spyre Therapeutics
Dec 17, 2025
Initiates: Buy
Price Target: $64
Current: $30.61
Upside: +109.08%
Wave Life Sciences
Dec 9, 2025
Maintains: Buy
Price Target: $16 → $30
Current: $13.84
Upside: +116.76%
Structure Therapeutics
Dec 9, 2025
Maintains: Buy
Price Target: $60 → $100
Current: $68.61
Upside: +45.75%
Nektar Therapeutics
Nov 26, 2025
Initiates: Buy
Price Target: $102
Current: $39.71
Upside: +156.86%
Agios Pharmaceuticals
Nov 26, 2025
Initiates: Buy
Price Target: $38
Current: $28.41
Upside: +33.76%
Rhythm Pharmaceuticals
Nov 25, 2025
Initiates: Buy
Price Target: $136
Current: $101.02
Upside: +34.63%
Biohaven
Nov 13, 2025
Maintains: Buy
Price Target: $28 → $14
Current: $11.11
Upside: +26.01%
Prime Medicine
Nov 11, 2025
Maintains: Neutral
Price Target: $5 → $4.25
Current: $3.94
Upside: +7.87%
Nov 11, 2025
Maintains: Buy
Price Target: $25 → $26
Current: $21.98
Upside: +18.29%
Nov 7, 2025
Maintains: Buy
Price Target: $31 → $33
Current: $22.72
Upside: +45.25%
Oct 29, 2025
Maintains: Buy
Price Target: $10 → $15
Current: $14.03
Upside: +6.91%
Oct 29, 2025
Downgrades: Sell
Price Target: $5
Current: $18.49
Upside: -72.96%
Aug 14, 2025
Maintains: Buy
Price Target: $13 → $10
Current: $2.10
Upside: +376.19%
May 15, 2025
Maintains: Buy
Price Target: $8 → $4
Current: $1.71
Upside: +133.92%
Dec 2, 2024
Initiates: Buy
Price Target: $12
Current: $4.02
Upside: +198.51%
Aug 9, 2024
Maintains: Buy
Price Target: $8 → $15
Current: $4.56
Upside: +228.95%
Jun 3, 2024
Reinstates: Buy
Price Target: $80
Current: $11.62
Upside: +588.76%
May 22, 2024
Maintains: Buy
Price Target: $10 → $14
Current: $3.33
Upside: +320.42%
May 9, 2024
Maintains: Buy
Price Target: $16 → $15
Current: $2.07
Upside: +624.64%
Sep 27, 2023
Maintains: Buy
Price Target: $33 → $50
Current: $26.03
Upside: +92.09%
Aug 9, 2023
Maintains: Buy
Price Target: $60 → $56
Current: $27.55
Upside: +103.27%